K
Krishna Pandey
Researcher at Rajendra Memorial Research Institute of Medical Sciences
Publications - 190
Citations - 3645
Krishna Pandey is an academic researcher from Rajendra Memorial Research Institute of Medical Sciences. The author has contributed to research in topics: Visceral leishmaniasis & Leishmania donovani. The author has an hindex of 27, co-authored 159 publications receiving 2973 citations. Previous affiliations of Krishna Pandey include Institute of Tropical Medicine Antwerp & Central Drug Research Institute.
Papers
More filters
Journal ArticleDOI
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Shyam Sundar,Prabhat K. Sinha,Madhukar Rai,Deepak Kumar Verma,Kumar Nawin,Shanawwaj Alam,Jaya Chakravarty,Michel Vaillant,Neena Verma,Krishna Pandey,Poonam Kumari,Chandra Shekhar Lal,Rakesh Kumar Arora,Bhawna Sharma,Sally Ellis,Nathalie Strub-Wourgaft,Manica Balasegaram,Piero Olliaro,Pradeep Das,Farrokh Modabber +19 more
TL;DR: Combination treatments for visceral leishmaniasis are efficacious and safe, and decrease the duration of therapy, thereby encouraging adherence and reducing emergence of drug-resistant parasites.
Journal ArticleDOI
Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani.
Bidyut Purkait,Ashish Kumar,Nilay Nandi,Abul Hasan Sardar,Sushmita Das,Sudeep Kumar,Krishna Pandey,Vidyananda Ravidas,Manish Kumar,Tripti De,Dharmendra Singh,Pradeep Das +11 more
TL;DR: It can be concluded that altered membrane composition, ATP-binding cassette transporters, and an upregulated thiol metabolic pathway have a role in conferring amphotericin B resistance in clinical isolates of Leishmania donovani.
Journal ArticleDOI
Phase 4 trial of miltefosine for the treatment of indian visceral leishmaniasis
Sujit K. Bhattacharya,Prabhat K. Sinha,Shyam Sundar,Chandreshar Prasad Thakur,T. K. Jha,Krishna Pandey,Vidyanand Rabi Das,Naveen Kumar,C. S. Lal,Neena Verma,Vijay Pratap Singh,Alok Ranjan,R. B. Verma,Gerlind Anders,Herbert Sindermann,Nirmal Kumar Ganguly +15 more
TL;DR: This study supports the use of miltefosine in an outpatient setting in an area where VL is endemic, and reports a cure rate similar to the 94% cure rate in hospitalized patients.
Journal ArticleDOI
Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus
Rishikesh Kumar,Muktikant Nayak,Ganesh Chandra Sahoo,Krishna Pandey,Mamta Chawla Sarkar,Yousuf Ansari,V. N. R. Das,Roshan Kamal Topno,Bhawna,Major Madhukar,Pradeep Das +10 more
TL;DR: Iron oxide nanoparticles (IO-NPs) with particle size in the range of 10-15 nm against pandemic influenza strain A/H1N1/Eastern India/66/PR8-H 1N1 and 08 fold reductions in virus found when treated with Iron oxide nanoparticle opens a new avenue for use of IP-NBP against virus infections.
Journal ArticleDOI
Inhibition of ABC Transporters Abolishes Antimony Resistance in Leishmania Infection
Jayati Mookerjee Basu,Ananda Mookerjee,Rajdeep Banerjee,Manik Chandra Saha,S. K. Singh,Ksudiram Naskar,Gayetri Tripathy,Prabhat K. Sinha,Krishna Pandey,Shyam Sundar,Sanjeev Bimal,Pradip Das,Soumitra Kumar Choudhuri,Syamal Roy +13 more
TL;DR: The results indicate that lovastatin, which can inhibit both P-gp and MRP1, might be beneficial for reverting Sb resistance in leishmaniasis as well as drug resistance in other clinical situations, including cancer.